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Abstract
Acute inflammation in response to both exogenous and endogenous danger signals can lead to the
assembly of cytoplasmic inflammasomes that stimulate the activation of caspase-1. Subsequently,
caspase-1 facilitates the maturation and release of cytokines and also, under some circumstances,
the induction of cell death by pyroptosis. Using a mouse line lacking expression of NLRP1, we
show that assembly of this inflammasome in cells is triggered by a toxin from Anthrax and that it
initiates caspase-1 activation and release of IL-1β. Furthermore, NLRP1 inflammasome activation
also leads to cell death, which escalates over three days following exposure to the toxin and
culminates in acute lung injury and death of the mice. We show that these events are not
dependent on production of IL-1β by the inflammasome but are dependent on caspase-1
expression. In contrast, MDP mediated inflammasome formation is not dependent on NLRP1, but
NLRP3. Taken together, our findings show that assembly of the NLRP1 inflammasome is
sufficient to initiate pyroptosis, which subsequently leads to a self-amplifying cascade of cell
injury within the lung from which the lung cannot recover, eventually resulting in catastrophic
consequences for the organism.
Introduction
NLRP1 was first characterized as a member of the CED-4 family of apoptotic proteins,
which are required to initiate programmed cell death in developing C. elegans (1–3).
Consistent with this relationship, two independent groups showed that over expression of
NLRP1/DEFCAP/NAC in mammalian cells leads to cell death through apoptosis (1, 2).
Functional homology with CED-4 was further demonstrated by in vitro studies with
macrophages that reported that NLRP1 is regulated by the anti-apoptotic proteins Bcl-2 and
Bcl-XL. Bcl-2 is homologous to CED-9, an antiapoptotic protein that binds CED-4(4).
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A possible mechanism by which NLRP1 could mediate cell death has been proposed based
on its detection in a protein complex named the inflammasome, which activates
inflammatory caspases (5). Thus, the first inflammasome complex to be described contained
the proteins caspase-1, caspase-5, ASC, and NLRP1. In later work using recombinant
proteins, caspase-1 activation was initiated by the NLRP1 protein alone in response to a
microbial component, muramyl-dipeptide (MDP), and ASC was not required, though it
enhanced caspase-1 activity(6). The protease caspase-1 mediates the production of mature
Interleukin (IL) -1β and IL-18 cytokines, which stimulate a pro-inflammatory immune
response and protect the organism from pathogen-induced death. However, a number of
lines of evidence indicate that robust activation of caspase-1 leads to induced cell death
under some circumstances. Cell death that is inflammation-associated and caspase-1
dependent has been termed pyroptosis (7). The downstream effects of pyroptosis are largely
unknown. Recently, pyroptosis was identified as a mechanism to clear intracellular bacteria.
Following Salmonella typhimurium infection, caspase-1 dependent pyroptosis resulted in
release of S. typhimurium from infected macrophages, and the bacteria were subsequently
killed by neutrophils (8).
NLRP1 is now recognized as one of a number of proteins that can form complexes capable
of supporting the maturation of caspase-1 in response to unique, but overlapping, danger and
pathogen signals. To date, these include NLRP1, NLRP3, NLRC4, NLRP6, NLRP7 and
absent in melanoma 2 (AIM2)(5, 9–16), although studies of NLRC5 and NLRP7 were
performed in human cells with gene knockdown strategies and NLRP1 by assembly in a cell
free system. Similar to many of the NLRs capable of forming an inflammasome, NLRP1
contains a pyrin domain that can bind ASC, a nucleotide binding domain (NBD or NATCH)
responsible for intramolecular folding and nucleotide triphosphate-dependent
oligomerization, a function to find domain (FIIND), a CARD domain that binds pro-
caspase-1, and a leucine-rich repeat domain (LRR). The LRR domain is believed to confer
the sensitivity of a given inflammasome to a particular pathogen or alteration in cellular
homeostasis, although direct evidence for this is not available. While the list of agents that
stimulate NLR/AIM2-dependent caspase-1 activation continues to expand, the intracellular
trigger for protein oligomerization remains unclear. To date, an in vitro protein
reconstitution assay showing formation of the NLRP1 inflammasome complex in response
to MDP treatment is the best display of stimulus-induced complex formation (6). Much of
the information regarding the activation of these human inflammasomes has been garnered
from experiments carried out in mice lacking the orthologous NLR gene, however, this has
not been achieved for NLRP1.
In mouse, three orthologs of the human NLRP1 gene have been identified, termed Nlrp1a,
Nlrp1b, and Nlrp1c (17). Using genetic studies, Boyden and Dietrich showed that the locus
encoding the Nlrp1 genes confers the sensitivity of some mouse lines to the lethal toxin of
Bacillus anthracis (17). Anthrax causes rapid tissue necrosis, circulatory collapse, and acute
respiratory failure due to fluid retention in the lung (18). Many of these pathologies can be
recapitulated in animal models by an exposure to Lethal Toxin (LT), which is a combination
of lethal factor (LF) and protective antigen (PA)(19), indicating that intoxication is
mediated, at least in part, by these factors. The mouse haplotype that confers sensitivity to
LT also carries mutations in the Nlrp1a and Nlrp1c genes that render them unlikely to direct
the expression of a functional protein (17). This suggests that it is the Nlrp1b allele carried
by some mouse strains that initiates the response to LT.
Here we report the generation of a mouse line lacking Nlrp1b expression. Using cells from
this line, we show that LT, but not MDP, can trigger the assembly of the murine NLRP1
inflammasome, leading not only to caspase-1 activation and IL-1β production, but also to
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pyroptosis. These events are sufficient to result in acute lung injury that escalates and leads
to morbidity within three days of activation of the NLRP1 inflammasome.
Materials and Methods
Mice
A vector was designed to inactivate the mouse Nlrp1b locus by removing a 16 kb segment
DNA extending from the middle of exon 3, which encodes the ATP binding NACHT
domain, to the promoter region of the gene and replacing it with a neomycin resistance
marker. An Xba I restriction digest site was added at the 3′ end of the Neor cassette
allowing detection of the mutant locus by Southern blot analysis. 129 ES cells carrying the
correctly modified Nlrp1b allele were mated with 129S6 mice (Taconic Farms Inc., Hudson,
NY) to maintain the mutation on this inbred genetic background.
The Nlrp3 −/− mouse line was generated by targeted mutagenesis in 129 ES cells using a
replacement type vector, which removed all Nlrp3 exons and replaced this segment of DNA
with the neomycin resistance gene.
The Casp1−/− mouse line was generated in 129 ES cells using a replacement type targeting
construct. Recombination with the endogenous Casp1/4 locus removed the entire coding
regions of both genes as well as 8 kb of DNA 5′ of Casp1 and 6 kb 3′ of Casp4. Chimeras
generated from the targeted ES cells were bred directly to 129S6 mice to maintain the
mutation on this genetic background.
The P2X7−/− mouse line was moved to the BALB/cByJ background by six consecutive
crosses to BALB mice (20).
All experiments were conducted in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals as well as the Institutional Animal Care and
Use Committee guidelines of the University of North Carolina at Chapel Hill.
Reverse Transcription PCR
RNA was isolated from intestine of wild-type 129 and Nlrp1b−/− mice with RNABee (Tel-
Test Inc., Friendswood, TX). RNA was reverse transcribed with Superscript III (Invitrogen,
Life Technologies, Grand Island, NY, USA) follow by PCR using primer sets specific for
Nlrp1a, Nlrp1b and Nlrp1c. Amplified products were visualized by gel electrophoresis.
Cell Culture
Bone marrow-derived macrophages (BMDM) were prepared by harvesting marrow from
femurs and tibias of 129+/+ and Nlrp1b−/− mice. Marrow was cultured for 7 days in IMDM
containing 15% L-cell-conditioned medium, 10% FBS, 2 mM L-glutamine, 150 U/mL of
penicillin, 150 μg/mL of streptomycin, and 57.2 μM 2-mercaptoethanol (all from GIBCO
Life Technologies, Grand Island, NY, USA). BMDM were incubated in OPTIMEM plus
Glutamax (GIBCO Life Technologies, Grand Island, NY, USA) containing varying
concentrations of lethal toxin (LT; List Biological Laboratories, Inc., Campbell, CA, USA)
for 4 hours and cell viability was assessed with the WST-1 reagent (F. Hoffmann-La Roche
AG, Basel, Switzerland). Peritoneal macrophages were elicited from wild-type, Nlrp1b−/−,
Nlrp3−/− and Casp−1−/− mice with an i.p. injection of 4 ml of 4% thioglycollate in PBS. 72
hours after injection, the peritoneal cavity was lavaged with DMEM and cells were plated
and incubated for one hour. Adherent cells were then washed twice with cold PBS and
cultured in DMEM containing 10% FBS, 2 mM L-glutamine, 150 U/mL of penicillin, 150
μg/mL of streptomycin, and 57.2 μM 2-mercaptoethanol (all from GIBCO Life
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Technologies, Grand Island, NY, USA). For LT treatments, macrophages were primed
overnight with 100 ng/ml ultra-pure LPS (Invitrogen, Life Technologies, Grand Island, NY,
USA), washed with PBS, and incubated with OPTIMEM plus Glutamax containing either
PBS or 1 μg/ml LT for 6 hours. Cytotoxicity was determined by measuring LDH release in
the cell supernatant by colorimetric assay following the manufacturer’s protocol (Clontech
laboratories, Mountain View, CA). For MDP, PGN, TiO2, and L18-MDP treatments, cells
were primed with 100 ng/ml ultrapure LPS for 6 hours, washed with PBS, and incubated in
OPTIMEM, 5 mg/mL TiO2, 5 mg/mL TiO2 + 10 mg/mL MDP, 5 mg/mL TiO2 + 20 mg/mL
PGN, 10 mg/mL MDP, 20 mg/mL PGN, or 1 mg/ml L18-MDP for 16 hours.
MDP Treatment of Mice
Mice received an i.p. injection of 5 μg LPS in 200 μl of PBS. 3 hours after LPS
administration, mice were i.p. injected with 50 μg of L18-MDP in 200 μl PBS. Serum and
peritoneal lavage fluid was collected 1.5 hours post-injection with L18-MDP.
LPS/LT and LPS/ATP treatments of Mice
129+/+ and Nlrp1b −/− mice were treated with 0.3 mg/kg body weight LPS intratracheally.
Two hours later, mice were treated with vehicle, 20 μg LT, or 50 μl 100 mM ATP
intratracheally. Two hours after the second treatment, mice were sacrificed and their lungs
lavaged with HBSS.
Lethal Toxin Treatment of Mice
Nlrp1b−/−, Il1β−/−, Casp−1−/−, Nlrp3−/− and appropriate 129+/+ control mice were dosed
intratracheally with vehicle or 20 μg LT and BAL fluid was collected at various time points.
The total number of cells in the BAL fluid was determined using a hemocytometer.
Protein analyses
IL-1β, IL-1α, KC, MIP-2 and CXCL15/lungkine levels were detected by ELISA as
recommended by the manufacturer (eBioscience, San Diego, CA and R&D Systems,
Minneapolis, MN). Albumin levels were evaluated by colorimetric assay according to the
manufacturer (Bethyl Laboratories, Montgomery, TX). BAL cell samples were processed to
isolate myeloperoxidase (MPO) enzyme, and its catalytic activity was evaluated by
colorimetric assay as a measure of neutrophil recruitment into the lungs. LDH release was
measured by colorimetric assay following the manufacturer’s protocol (Clontech
Laboratories, Mountain View, CA). Results were compared to the total LDH released from
cells treated with 1% Triton-X (100% lysis control). For western blot analysis, protein from
BAL fluid was concentrated using a Microcon YM-30 column (Millipore, Billerica, MA)
and subsequently quantified by BCA assay (Thermo Scientific Pierce, Rockford, IL). 20 μg
of total protein was separated by SDS/PAGE, transferred onto a PVDF membrane, and
incubated with IL-1β (AF-401-NA, R&D Systems, Minneapolis, MN), caspase-1 (sc-514,
Santa Cruz Biotechnology Inc., Santa Cruz, CA), HMGB1 (ab12029, Abcam Inc.,
Cambridge, MA), or GAPDH (#3683, Cell Signaling Technology, Danvers, MA, USA)
antibodies.
Histology
Lungs were inflated with 10% formalin via a tracheal cannula, removed from the thoracic
cavity, and fixed overnight in formalin. Sections of the left lobe of the lung were stained
with hematoxylin-eosin. Digital images of the sections were captured under bright field
mode using Olympus BX61 Upright Fluorescence Microscope (Olympus, Center Valley,
PA, USA) and Velocity software (PerkinElmer Life and Analytical Sciences, Waltham, MA,
USA). Whole lung sections and at least four images of representative areas of each section
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were captured. For 2x images, a background image was digitally subtracted using ImageJ
software (National Institutes of Health, Bethesda, MD).
FACS analysis
BAL was collected two hours after intratracheal instillation of 20 μg LT or vehicle. Cells
were stained with fluorescently labeled caspase inhibitors FAM-YVAD-FMK (caspase-1) or
FAM-DVED-FMK (caspase-3) and with 7-Amino-Actinomycin (7-AAD, BD Bioscience,
Franklin Lakes, NJ USA) according to manufacturer’s instructions (Cell Technology, Inc.,
Mountain View, CA, USA). For whole lung cell suspension, isolated lungs were cut into
pieces and incubated for 1 h in digestion medium (RPMI, collagenase IV 12 mg/ml, DNase I
10mg/ml) at 37°C. A single cell suspension was prepared by passing through 70 μm cell
strainer (BD Bioscience, Franklin Lakes, NJ USA). Red blood cells were removed by
incubation in lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA). Cell were
incubated with Fc block, and stained for CD45, Mac-I, and GR-1 or CCR-2 (all from BD
Bioscience, Franklin Lakes, NJ USA). FACS analysis was done using a Beckman Coulter
CyAn ADP Analyzer (Beckman Coulter, Inc., Brea, CA). Data were analyzed using FloJo
(TreeStar, Ashland, OR) software.
Statistical analyses
Data is represented as mean ± standard error of the mean. A student’s t-test, one-way
ANOVA with Tukey’s posttest, or two-way ANOVA with Bonferroni posttest were used to
determine the statistical probability of differences between experimental cohorts. *, p <
0.05; **, p < 0.01; ***, p < 0.001; ***, p < 0.0001.
Results
Generation of mice lacking Nlrp1b
The mouse Nlrp1 locus contains three closely related genes designated Nlrp1b, Nlrp1c, and
Nlrp1a. To generate a mouse lacking NLRP1 function, we took advantage of the fact that, in
the 129 mouse, Nlrp1a and Nlrp1c do not encode functional proteins. Therefore, inactivation
of the functional Nlrp1b gene is expected to yield an Nlrp1−/− animal. A vector was
designed that, upon homologous recombination at the Nlrp1b locus, results in the
replacement of the 5′ portion of exon 3 as well as exons 1 and 2 and the promoter region of
the gene with a neomycin resistance marker. Using Southern blot analysis, we confirmed the
generation and transmission of the mutant Nlrp1b allele (Fig. 1B). The mutant allele was
maintained on the 129 genetic background by breeding chimeras generated from the
modified ES cells directly to 129S6 mice. The impact of the Nlrp1b mutation was, therefore,
studied here in co-isogenic cohorts of animals. No differences were noted in the growth or
the behavior or fertility of the Nlrp1b−/− mouse line, and expression analysis indicated that
the mutation generated a null allele. Both gross and histological analysis revealed no lesions
and no changes in the development. RNA analysis confirmed the absence of Nlrp1a-c
transcripts (Fig. 1C).
Nlrp1b−/− macrophages are protected from LT induced cell death
Genetic studies indicate that expression of a functional Nlrp1b allele confers sensitivity of
129S6 cells to anthrax lethal toxin (LT)(17). If this is indeed the case, and if the targeting
event created a null allele as expected based on RNA analysis of tissue from the Nlrp1b−/−
line, then macrophages from mice homozygous for the mutant allele should be resistant to
LT. To test this, we first cultured macrophages from the bone marrow (BMDM) of 129S6
(129+/+) and Nlrp1b−/− animals and examined their viability in the presence of increasing
amounts of LT. A decrease in the viability of 129+/+ macrophages was noted even upon
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exposure to very low levels (1 ng/mL) of LT. At doses greater than 10 ng/mL, virtually all
cells succumbed to the toxin. In contrast, no decrease in viability of the Nlrp1b−/− cells was
observed following exposure to increasing doses of toxin (Fig. 2A).
LT mediated cell death and IL-1β and IL-1α release are caspase-1 dependent but NLRP3
independent
We next determined whether the LT mediated cell death coincided with the release of IL-1β
and IL-1α. Thioglycolate-elicited peritoneal macrophages were collected and treated for 12
hour with LPS to induce expression of cytokines prior to exposure to LT. Six hours after the
addition of LT, the cell supernatant was collected. LT mediated cell death was assessed by
measuring the levels of the cytoplasmic enzyme, lactate dehydrogenase (LDH), released into
the medium. IL-1β and IL-1α release were determined by ELISA. LDH levels in the
supernatant collected from 129+/+ cultures corresponded to 75% of total cellular LDH
content. Only low levels of LDH (0.8%) were detected in the supernatant from Nlrp1b−/−
macrophages. Casp−1−/− macrophages also released small amounts of LDH compared to
129+/+ cells (9.7%; Fig. 2B). Although the levels of LDH released by the Casp−1−/−
cultures were higher than those observed in the Nlrp1b−/− cultures, these results indicated
that cell death is largely NLRP1b and caspase-1 dependent. NLRP1b has been reported to
collaborate with other NLR proteins (21). We therefore examined the possibility that, while
NLRP1b was required for initiating the response to LT, subsequent recruitment of NLRP3
was required for caspase-1 activation and cell death. To test this, an Nlrp3 deficient, 129S6
co-isogenic mouse line was generated by homologous recombination. Nlrp3−/−
thioglycolate-elicited macrophages were collected and treated with LPS followed by LT. No
significant difference in the survival of LT-treated 129+/+ and Nlrp3−/− cells was observed
(Fig. 2B). Production and release of IL-1β and IL-1α by LT-treated cells were detected by
ELISA in supernatants collected from 129+/+, Nlrp1b−/−, Nlrp3−/−, and Casp1−/−
macrophages. While levels of IL-1β and IL-1α in the supernatant collected from the LT-
treated Nlrp3−/− cells did not significantly differ from LT-treated 129+/+ cells, in Casp1−/−
and Nlrp1b−/− cells, the release of IL-1β and IL-1α was attenuated to level similar to PBS-
treated controls. (Fig. 2C, D).
NLRP3, not NLRP1b, is essential for MDP and PGN mediated IL-1β release
In vitro assembly of the human NLRP1 inflammasome and activation of caspase-1 can be
initiated by exposure of inflammasome components to bacterial peptidoglycans (6). We
therefore asked whether NLRP1b was necessary for inflammasome assembly and processing
of IL-1β by mouse macrophages in response to peptidoglycan (PGN) or its degradation
product muramyl dipeptide (MDP). Peritoneal macrophages were collected from 129+/+,
Nlrp1b−/−, Nlrp3−/− and Casp1−/− mice. Cells were treated with MDP and PGN alone or in
combination with titanium dioxide (TiO2). TiO2 has been reported to bind to
peptidoglycans, increasing their uptake by macrophages (21). Consistent with this report, the
release of IL-1β in response to PGN and MDP in the absence of TiO2 was below the level of
detection. The addition of TiO2 together with either PGN or MDP resulted in a robust
release of IL-1β that was approximately twice that observed with TiO2 alone. However, this
response was unaltered in the Nlrp1b−/− cells. Instead, the response to TiO2 alone or TiO2
in combination with MDP or PGN was dependent on NLRP3 expression. As expected, the
maturation and release of IL-1β was not observed in Casp1−/− cells (Fig. 3A). To further
verify the normal response of Nlrp1b−/− macrophages to MDP, we examined the response
of 129+/+, Nlpr1b−/−, Nlrp3−/− and Casp1−/− macrophages to L18-MDP. L-18-MDP is a
lipidated form of MDP that improves uptake of the molecule. Again, the response of the
peritoneal macrophages to MDP was dependent on NLRP3 but not NLRP1b (Fig. 3B). In
vivo studies on 129+/+ and Nlrp1b −/− mice exposed to L18-MDP also failed to support a
role for NLRP1b in the response to MDP (Fig. 3C and D).
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In vivo LT mediated processing and release of IL-1β is Nlrp1b-dependent
We next verified that NLRP1b could mediate IL-1β processing in vivo. To test this, pro-
IL-1β expression in the lung was induced by intratracheal (i.t.) instillation of LPS at 0 h and
followed by LT (LPS/LT) or ATP (LPS/ATP) treatment at 2 h to induce IL-1β processing.
Bronchoalveolar lavage (BAL) fluid was collected at 4 h, and levels of mature IL-1β were
determined by ELISA. While no IL-1β was observed in the BAL fluid of the vehicle-treated
animals, treatment with LPS/ATP resulted in high levels of IL-1β in the lavage fluid of
129+/+ and Nlrp1b−/− animals. LPS/LT treatment resulted in release of IL-1β in 129+/+
mice but not in mice lacking NLRP1b (Fig. 4A). Similarly to IL-1β, the release of IL-1α
following LPS/LT treatment was dependent on NLRP1b (Fig. 4B). To verify that the IL-1β
present in the BAL fluid represented processed cytokine, proteins were analyzed by western
blot. Processed IL-1β as a p17 fragment was detected in the BAL fluid from 129+/+ mice
treated with LPS/LT, but not in BAL collected from Nlrp1b−/− animals (Fig. 4C).
Consistent with this, amount of processed caspase-1 in the BAL fluid from the Nlrp1b−/−
animals treated with LT was substantially reduced compared to that observed in the 129+/+
LT-treated animals (Fig. 4C).
Mice lacking NLRP1 are protected from LT mediated acute lung injury
We next asked whether, in addition to altering the processing and release of IL-1β, the
absence of NLRP1b would protect mice from the development of LT-induced acute lung
injury. 129+/+ and Nlrp1b−/− mice were instilled with LT, and the progression of disease
was monitored over 24 hours. LT induced a rapid and progressive disease in the 129+/+
mice that was characterized by a dramatic increase in KC, MIP-2, and HMGB1 levels. A
small increase in IL-1β and CXCL15 were also measured in the LT-treated animals (Fig.
5A–E). A parallel increase in the cellularity of the BAL fluid was observed in mice that
received the toxin. However, cell numbers in the BAL fluid peaked at 6 hours, and then
remained largely unchanged throughout the course of the disease (Fig. 5F). The failure to
observe a progressive increase in cell numbers as the health of the mice declined likely
reflects a balance between cell death and cell recruitment. Consistent with this
interpretation, the BAL fluid collected from animals with more advanced disease contained
increasing levels of fragmented cells that were difficult to categorize based on
morphological criteria (data not shown). Furthermore, LDH levels in the BAL fluid
continued to increase throughout the experiment, while the number of intact cells present in
the BAL fluid remained largely unaltered (Fig. 5G). After 24 hours, alterations in lung
permeability, determined by measurement of the levels of albumin in the BAL fluid, became
apparent (Fig. 5H). Recruitment of cells into the airways of the Nlrp1b−/− mice was
significantly lower than that observed in 129+/+ mice. This was consistent with the failure
of LT to lead to increase in levels of KC, MIP-2, IL-1β, CXCL15, or HMGB1. The latter is
an indication of cell death and has been previously observed in Klebsiella pneumonia
infected Nlrp3−/− mice (22). Levels of LDH in the BAL fluid were significantly lower than
those observed in the 129+/+ animals and did not significantly increase during the course of
the experiments. The permeability of the lungs was not altered, as albumin levels remained
low throughout the experiment (Fig. 5A–H). The majority of the cells recruited to the lung
after exposure to LT are neutrophils and their recruitment is attenuated in the mice lacking
NLRP1 as shown by quantitative analysis of myeloperoxidase levels in cell pellet obtained
from the BAL at 48 and 72 h post LT-treatment (5I). Similarly, FACS analysis of single cell
suspensions of whole lung revealed that the NLRP1 deficient mice had significantly lower
numbers of total lung neutrophils even at this earlier time point (16 h) (5J, K). The
recruitment of CCR2+ monocytes has been noted in models of lung injury and inflammation
(23). We therefore examined the recruitment of these cells to the lung in single cell
preparations of whole lung using antibodies specific for this population. As can be seen in
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figure 5L–M, inflammatory monocyte numbers were significantly reduce in the lungs of the
NLRP1 deficient animals compare to 129+/+.
Progression of Acute Lung injury in Nlrp1+/+ animals
To further compare the progression of lung disease in 129+/+ and Nlrp1b−/− animals, we
evaluated changes in the structure of the lungs collected from mice at various time points
after LT exposure. Histological changes were assessed by analysis of hematoxylin-eosin
stained tissue sections prepared from the left lobe. As expected, no difference was observed
in lungs collected from vehicle-treated Nlrp1−/− and 129+/+ animals (Fig. 6A and E).
Exposure to LT induced diffuse lung injury, and the extent of the damage became more
apparent in samples collected at later time points, especially 72 h after exposure to LT.
Visualization of whole lung sections showed diffuse alveolar damage and evidence of
hemorrhaging in multiple regions of the lobe (Fig. 6B–D). Neutrophils and macrophages
could be detected in the alveolar walls and interstitial spaces surrounding the alveolar
airways (Fig. 6I). However, consistent with the cellularity of the BAL fluid, the number of
cells in the alveoli did not increase notably as the injury progressed. Deposition of
proteinous fibers in the airways was observed, consistent with significant trapping of red
blood cells within the alveolar spaces (Fig. 6J, K). While inflammatory infiltrates were
observed in the lymphatics, the airway epithelial cells remained largely intact. Remarkably,
lungs of Nlrp1b−/− mice were largely spared from injury (Figs. 6F–H). Some increase in
inflammatory cell numbers was observed at 48 and 72 h but was less extensive compared to
129+/+ mice. The airways and alveolar architecture were maintained, and no hemorrhaging
was observed even at 72 h (Fig. 6L–N). Consistent with these histological changes, 129+/+
mice exhibited significant inflammation, compromised of barrier function, lethargy, and
decline in body temperature, and displayed morbidity requiring euthanasia (data not shown).
In contrast, mice lacking NLRP1b were largely protected from the sequel of events that
followed exposure of the lung to LT. Even at 72 h post-treatment, Nlrp1−/− mice appeared
normal and could not be distinguished from untreated littermates.
LT mediated lung injury is dependent upon caspase-1 activation
Since exposure of the mouse airways to LT was accompanied by a modest, NLRP1b-
dependent increase in IL-1β measured in the BAL fluid (Fig. 5C), we further assessed the
contribution of this NLRP1b pathway to the development of acute lung disease. We
generated cohorts of mice that expressed the 129+/+ 129S6 Nlrplb gene, which confers the
ability to respond to LT, but lacked Casp-1 or Il1β genes. The 129S6 mouse also carries a
mutant Casp-4 (alias Casp-11) (24). Thus all the animals included in the study also lack
expression of Casp-4. These mice and their Casp-1 +/+ or Il1β +/+ littermates were exposed
i.t. to LT, and the development of lung disease in the two groups of animals was compared.
If the lung disease observed in the LT-treated animals is the consequence of pyroptosis, a
caspase-1 mediated cell death, we would expect that the Casp−1−/− mice would be
protected from the toxin. Indeed, the lack of caspase-1 protected the mice from LT induced
lung inflammation. Inflammatory cell recruitment was reduced in Casp-1−/− mice exposed
to LT compared to Casp-1+/+ mice (Fig. 7A). Cell death was also significantly reduced in
Casp-1−/− mice (Fig. 7B), as expected based on our in vitro analyses of Casp-1−/−
macrophages (Fig. 2B). Correspondingly, vascular permeability was less severe in Casp-1−/
− mice compared to Casp-1+/+ mice, although the difference did not reach significance by
72 h (Fig. 7C). Levels of the pro-inflammatory mediators KC and CXCL15 were also
significantly lower in Casp-1 deficient mice (Fig. 7D and E). In contrast, the lack of IL-1β
failed to protect mice from the development of disease. No significant differences in
inflammation or disease pathology were observed between Il-1b+/+ and Il-1b−/− mice (Fig.
7F and G and data not shown).
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LT induces pyroptosis of alveolar macrophages
We next examined whether caspase-1 activity was critical in the initiation and progression
of lung disease in the 129+/+ LT-treated animals. Mice were treated with LT, and cells
present in the airways were collected by BAL at 2 hours after treatment. The viability of the
cells was determined by staining with 7-AAD. Over 50% of the cells collected from 129+/+
animals were non-viable based on this criterion, while greater than 95% of the cells
collected from the Nlr1b−/− or Casp-1−/− mice failed to take up the dye (Fig. 8A). Thus,
again, Casp-1−/− and Nlrp1b−/− cells were protected from cell death induced by LT. To
determine if catalytic activity of caspase-1 mediated cell death in 129+/+ animals, we
stained the airway cells collected by BAL with the fluorescently-labeled caspase-1
preferring substrate and inhibitor, FAM-YVAD-FMK. This inhibitor binds irreversibly to
activated caspase-1. Nearly all the cells collected from the 129+/+ animals were stained with
the caspase-1 inhibitor, while no significant change in the mean fluorescent intensity was
measured in the cells collected from similarly treated Nlrp1b−/− animals. As expected, no
caspase-1 activity was detected in cells collected in the BAL fluid of Casp-1−/− mice. We
next determined whether LT either directly or indirectly resulted in activation of caspase-3.
Only a small shift in the mean fluorescent intensity was observed in BAL cells from 129+/+
animals, but no cells from Casp-1−/− or Nlrp1b−/− animals were stained with the caspase-3
preferring fluorescent inhibitor FAM-DVED-FMK (Fig. 8B). Caspase-1 activation in
macrophages can occur downstream of cell death in response to the leakage of some of the
intracellular contents from dying cells. For example, the accumulation of ATP and/or uric
acid in the extracellular milieu stimulates caspase-1 activity in nearby cells, and this
activation is dependent upon NLRP3, but not NLRP1 (25–27). However, we did not observe
any attenuation of lung disease due to the absence of the NLRP3 inflammasome in Nalp3−/−
mice (data not shown), suggesting that, similar to LT induced cell death in macrophages in
vitro (Fig. 2), LT induced pyroptosis in alveolar macrophages is NLRP1b and caspase-1
dependent but NLRP3 independent. Similarly, loss of P2X7 did not alter the development of
severe lung disease after Nlrp1b activation.
Discussion
Early studies using human cell free reconstitution showed that NLRP1, in the presence of
muramyl dipeptide (MDP), could form a complex with caspases-1 capable of augmenting
autoactivation of the caspase and subsequent cleavage of pro IL-1β into its active form (6).
ASC enhanced this activity but was not essential for caspase-1 cleavage. The requirement
for MDP to initiate the assembly of the complex suggested that at least one of the functions
of the NLRP1 inflammasome was intracellular surveillance for this bacterial cell wall
component. These initial observations linking MDP and the NLRP1 inflammasome were
supported by indirect evidence collected from a number of studies that followed. Mouse
macrophages lacking NOD2 failed to produce IL-1β in response to MDP, clearly defining a
role for this protein in the response to MDP (21). This observation was consistent with
earlier studies that showed that introduction of NOD2 into cell lines allowed these cells to
respond to MDP (28, 29). To reconcile this with the cell free studies showing MDP
dependent assembly of the NLRP1 inflammasome, IL-1β production in response to MDP
was examined in the human monocyte line, THP-1, as well as HEK293T cells transfected
with various components of the inflammasome. In this study, complicity between NOD2
and NLRP1 in IL-1β release was supported by demonstrating association of NLRP1 with
NOD2 using co-immunoprecipitation strategies after MDP exposure as well as
demonstration of a decrease in release of IL-1β after RNAi knockdown of NLRP1
expression. MDP has also been used to stimulate NLRP1 inflammasome assembly in studies
focused on identifying regulators of NLRP1 activity, again using THP-1 cells. While
NLRP1 dependent maturation and release of IL-1β is also reported in this study,
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interpretation of these studies is complicated by the treatment of cells with ATP, a potent
stimulator of NLRP3 inflammasome assembly (4).
Species conservation in the ability of a particular PAMP to trigger a specific inflammasome
has generally been observed, albeit in the case of humans these studies are heavily
dependent on use of the THP-1 cell line. We were, therefore, surprised to observe no
difference in IL-1β release between wild type and NLRP1 deficient cells in response to
MDP. This was true even when, as in previous studies, we utilized TiO2 to increase uptake
of MDP by peritoneal macrophages. Lack of NLRP1 did not alter the response to L18-MDP,
a derivative with improved cellular uptake. In vivo studies also failed to define a role for
NLRP1 in the response to this bacterial wall component. In all of these models, increase in
IL-1β release was entirely dependent on Nlrp3 expression. No significant increase in release
of IL-1β was observed from macrophages isolated from the 129 Nlrp1−/− co-isogenic mice
after stimulation with MDP, and Nlrp3−/− mice were protected from elevations in serum
IL-1β after MDP exposure. Thus our results support a model in which NLRP3 rather than
NLRP1, alone or in cooperation with NOD2, mediates IL-1β processing and release in
response to MDP. Our findings are consistent with a previous study examining the response
of NOD2 and NLRP3 deficient bone marrow derived macrophages to MDP (30). No
increase in IL-1β release was observed after stimulation of either Nod2−/− or Nlrp3−/−
cells, suggesting a possible collaboration between these two NLRs in caspase-1 activation
and maturation in response to MDP exposure. These findings together with our results raise
the possibility that there are species differences in assignment of functions to
inflammasomes: the importance of NLRP3 in the response to MDP being limited to mouse,
with NLRP1 carrying out the orthologous function in human cells. However this
interpretation is not consistent with previous studies using a human ectopic expression
system in which MDP was shown to stimulate the NLRP3 (31). Furthermore, Martionon et
al show that cells from Muckle-Wells patients, who carry gain of function mutations in
NLRP3, display increased IL-1β secretion in the presence of MDP. Taken together, our
study and the differences between previous reports, depending on the system used in the
study, suggest that the role of NLRP1 in the response to MDP needs to be re-evaluated.
Given the failure of MDP to stimulate the inflammasome, we used anthrax lethal toxin (LT)
to define events following NLRP1 inflammasome assembly in peritoneal macrophages and
in vivo in the lung. Consistent with previous observations (32), the most dramatic
consequence of exposure of macrophages to LT was cell death as monitored by increase in
cellular dehydrogenase levels in vitro in culture supernatant. In vivo this was manifested as
an increase in LDH in the BALF collected from LT treated animals. When cells were treated
with LPS prior to exposure to LT, IL-1β release was also observed. Caspase-1 deficient cells
and Casp1−/− mice are largely protected. As 129 mice lack a functional Casp-4 (formerly
Casp-11) gene, it is clear that activation of caspase-1 by the NLRP1 inflammasome is
sufficient for both IL-1β processing and cell death (24). The dependence of cell death on
caspase-1 and the accompanying release of cytokines indicate that NLRP1b activation can
lead to macrophage pyroptosis. Activation of this pathway is also observed in vivo.
Exposure of the mouse airways to LT resulted in activation of caspase-1 in alveolar
macrophages, resulting in cell death. Again, the accompanying increase in IL-1β release was
only observed if the animals had been exposed to LPS, which stimulates transcription of this
cytokine.
The cellular events critical for engagement of the NLRP1 inflammasome that follow LT
exposure have not been defined, nor is it clear why the Nlrp1b allele carried by a number of
inbred mouse lines, including BALB/c and 129, is uniquely activated by this toxin. LT is a
zinc metalloproteinase, and cleavage of MEK by this proteinase and subsequent alteration in
the activity of ERK, JnK and p38 pathways has been documented by a number of groups
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(33–36). These events do not distinguish the LT resistant strains such as C57BL/6 from LT
sensitive strains such as 129. LT inactivation of MEK occurs equally in both 129 and
C57BL/6 cells, even though the latter cells do not undergo rapid pyroptosis, but rather after
an extended period of time begin to undergo apoptosis (35, 37). Interestingly, it was recently
discovered that the N-terminal domain of NLRP1 from LT- sensitive strain is cleaved by LT
and that the cleavage is essential for NLRP1 inflammasome activation, caspase-1 activation,
IL-1β production and pyroptotic macrophage death. This observation suggests that allelic
differences lead to alterations in the sensitivity of NLRP1 to cleavage by proteases. In this
case the 129 and BALB alleles show dramatic increase in sensitivity to lethal toxin, but it is
equally likely that the many common coding variants in the mouse and human gene alter the
sensitivity of NLRP1 to other proteases, thus modifying the activation of this inflammasome
in response to various innate stimuli (38),(39). It is apparent that, once assembly of the
Nlrp1b inflammasome is triggered, it leads to cellular events that mimic those of other
inflammasomes, namely caspase-1 recruitment and autoactivation and IL-1β maturation and
release. Cell death requires caspase-1. However we cannot rule out the possibility that the
other activities of LT leave the cells vulnerable to pyroptosis.
Similarly to LT exposure, infection with virulent strains of Bacillus anthracis results in
caspase-1 activation and IL-1β production and release. However, contrary to LT treatment,
caspase-1 as well as IL-1β protects infected animals against B. anthraxis infection (40).
Although it was shown that LT is a major virulence factor during B. anthracis infection,
other virulence factor are probably involved during infection with B. anthracis compare to
sterile induction of inflammation by LT. This is supported by recent data, showing that mice
lacking major components of other inflammasomes (Nlrc4) and receptor for MDP (Nod2)
are critical for protection from virulent B. anthracis infection (40).
In the lung, the activation of NLRP1 has catastrophic consequences, resulting in changes
that mimic some aspects of acute respiratory distress (ARDS)(41). A notable feature of this
inflammation is that, unlike many other sterile models of ARDS disease, NLRP1 activation
results in progressive damage to the lung. In contrast, exposure of mouse lungs to endotoxin
results in a rapid induction of chemokines followed by an influx of neutrophils/monocytes
and leukocytes. However the inflammation rapidly resolves, and the majority of animals
show no evidence of disease at 72 hours after treatment. NLRP1 activation also results in a
rapid induction of chemokines, including those most relevant for neutrophil recruitment KC
(CXCL1) and MIP-2 (42). Lungkine, (CXCL15) which is expressed at high levels by lung
airway epithelial cells (43) and is protective in bacterial pneumonia is also found at higher
levels in the inflamed lung (44). However, unlike LPS induced models of lung injury,
damage continues to accumulate, with visible lesions apparent upon necropsy 72 hours after
NLRP1 activation. It is likely, therefore, that the initial pyroptosis of the resident
macrophages initiates events that overwhelm the homeostatic mechanisms of the lung.
Consistent with this, the dramatic loss in barrier function becomes apparent long after the
initial activation of the inflammasome by LT. An important clue to the mechanism(s)
leading to organ failure is the steady increase in LDH levels in the BALF. This indicates that
after the initial NLRP1 dependent pyroptosis, cell death in the lungs continues and in fact
increases. Susceptible cells may include structural cells of the lung and cells recruited by the
initial pyroptosis of resident macrophages, neutrophils and monocytes. Consistent with
pyroptosis of resident cells high levels of HMGB1 are observed in the BAL immediately
after exposure to LT. Elevated levels observed at later time points with continued detection
of IL-1β suggest that pyroptosis continues. In these cases it is possible that cell death is
mediated by DAMPs (damage associated molecular patterns) released when the cells
undergo the NLRP1 dependent pyroptosis in response to LT.
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Although it is well established that IL-1β can induce inflammation by stimulating resident
immune cells to produce chemokines (45), the IL-1β observed in this model does not
contribute significantly to the development of ARDS like disease. In contrast, the lungs of
the Casp1−/− mice were protected, suggesting that caspase-1 activation and the resulting
cell death, rather than IL-1β processing, is the critical outcome of NLRP1 activation in this
model. We have not yet identified the critical factors/cytokines released by the initial
NLRP1 dependent pyroptosis that lead to escalation in lung injury. ATP is released upon
cell death and could lead to activation of the NLRP3 inflammasome in neighboring cells,
inducing further cytokine release and pyroptosis. A role for this pathway is not supported by
the observation that neither the Nlrp3−/− or the P2X7−/− mice were protected from lung
damage. It also makes it unlikely that uric acid released from dying cells contributes to
further tissue damage, as this DAMP has also been shown to rely on the NLRP3
inflammasome. HMGB1 released from pyroptotic cells can induced acute inflammation
characterized by increased cytokine production and neutrophil recruitment (46). In animal
models of systemic injury, inhibition of HMGB-1 is reported to attenuate pulmonary
endothelial barrier dysfunction. Thus it is possible that release of this intracellular protein
contributes to loss of vascular integrity, marked by hemorrhaging and increase in serum
proteins in the airways, observed in this NLRP1 dependent model of ARDS. Further studies
using specific inhibitors of factors released upon initial activation of the NLRP1
inflammasome as well as mice in which NLRP1 expression is limited to specific cell
populations should allow further definition of the events that lead from initial activation of
NLRP1 to acute and progressive lung disease.
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Figure 1. Generation of a Nlrp1 deficient mouse line
(A) A schematic of the endogenous Nlrp1b locus, the targeting vector designed to disrupt
the gene and the expected structure of the gene after homologous recombination. (B)
Southern blot analysis of DNA from ES cells (upper panel) and from tail biopsies of pups
generated from the intercross of mice carrying the modified Nlrp1b locus (lower panel)
verified correct recombination of the plasmid with the endogenous locus and transmission of
this allele through the germline. The expected 9.5kb XbaI fragment is observed in wild type
ES cells and in mice carrying a wild type Nlrplb allele. Homologous recombination
introduces a novel XbaI site reducing the size of the DNA fragment that binds to the probe
to 7.7 kb. (C) RNA was prepared from the jejunum of 129 and Nlrp1b−/− mice and
expression of all three Nlrp1 genes was examined by PCR using primers specific for each
gene. As expected, 129S6 mice express only Nlrp1b, and this expression was not observed
on analysis of RNA prepared from mice homozygous for the mutant allele.
Kovarova et al. Page 16













Figure 2. Lethal toxin mediated cell death and IL-1β and IL-1α cytokine release from
macrophages
(A) BMDMs from 129+/+ and Nlrp1b −/− mice were incubated with LT for 4 hours and cell
viability was determined with the WST-1 reagent. (B–D) Thioglycolate-elicited peritoneal
macrophages were primed with 100 ng/ml ultra-pure LPS overnight and subsequently
incubated for 6 hours in presence of 1 μg/ml LT. Cell death was determined by LDH
activity in supernatant and expressed as the percentage of total cellular LDH activity (B).
IL-1β (C) and IL-1α (D) release to supernatant was detected by ELISA. n=4 for 129+/+,
Nlrp1b −/−, Nlrp3 −/−; n=3 for Casp-1 −/−. * p<0.05, ** p<0.01, *** p<0.001
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Figure 3. NLRP1b is not required for IL-1β release induced by MDP or PGN
(A) Thioglycolate-elicited peritoneal macrophages were primed with 100 ng/ml ultrapure
LPS for 6 hours and incubated in OPTIMEM with indicated concentration of TiO2, MDP,
PGN or combinations of those stimuli for 16 hours. IL-1β from supernatants was detected
by ELISA, n=4. (B) Thioglycolate-elicited peritoneal macrophages were primed as in (A)
follow by treatment with 1 mg/ml L18-MDP, 5 mg/ml TiO2 or 5 mg/ml TiO2 and 10 mg/ml
MDP for 16 h. IL-1β was detected by ELISA in supernatants, n=4 (C, D) 129+/+ (black)
and Nlrp1b −/− (white) mice were injected i.p. with 5 μg LPS. 3 hours later mice were i.p.
injected with 50 μg of L18-MDP. Serum and peritoneal lavage fluid (PLF) was collected 1.5
hours postinjection with L18-MDP. The total number of inflammatory cells in peritoneal
lavage fluid (60% neutrophils) (C) and IL-1β in the serum and PLF measured by ELISA (D)
were determined, n = 13 for 129+/+, 14 for Nlrp1b −/−, # p<0.0001.
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Figure 4. Nlrp1b is required for lethal toxin mediated release of IL-1β and IL-1α in the lung
129 +/+ (black) and Nlrp1b −/− (white) mice were treated with 0.3 mg/kg LPS or PBS i.t. at
0 h, and with PBS, 1 μg LT or 50 μl of 100 mM ATP i.t. at 2 h. BAL fluid was collected at
4 h after the initial treatment. IL-1β (A) and IL-1α (B) in the BAL determined by ELISA.
(C) Processed IL-1β and caspase-1 proteins from concentrated BAL fluid analyzed by
western blot, 20μg of protein per line, 2 representative results from 5 independent
experiments shown.*** p<0.001, # p<0.0001, n=1 for PBS, n=10 for LPS/LT, n=4 for LPS/
ATP.
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Figure 5. Nlrp1b−/− mice are protected from lethal toxin-induced lung injury
129 +/+ (black) and Nlrp1b −/− (white) mice were treated with 20 μg LT i.t. BAL fluid was
collected at 0 h, 2 h, 6 h, 16 h, and 24 h after treatment. MIP-2 (A), KC (B), IL-1β (C), and
CXCL15/lungkine (D) in the BAL fluid were detected by ELISA. (E) Western blot of
HMGB1 protein in concentrated BAL fluid; GAPDH was used as a loading control, 20μg of
protein per line. Results shown are representative of 3 independent experiments. (F) The
total number of inflammatory cells in BAL fluid. (G) Cell death in BAL fluid assessed by
LDH activity. (H) Vascular permeability evaluated as a concentration of albumin in the
BAL fluid, measured by colorimetric assay. (I) Myeloperoxidase (MPO) level in BAL cell
pellet collected from 129+/+ and Nlrp1b−/− mice 48 and 72 h after LT treatment. (J–N)
FACS analysis of whole lung cell suspension from 129+/+ (J, L) and Nlrp1b−/− mice 16 h
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post-LT treatment (K,M). CD 45+ cells were gated and analyzed for Mac-1 and GR-1
epitope (J, K) or Mac-1 and CCR-2 epitope (L, M). (J–M) representative from 3 independent
experiment, quantitative analysis of CD45+Mac-1+CCR2+ cells (N). n=2 per genotype at
0h, n=5 per genotype at 2h, n=6 per genotype at 6h, n=3 per genotype at 16h, n=7 per
genotype at 24–72 h. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 6. Histological analysis of lethal toxin-induced lung injury
Micrographs of H&E-stained sections of lungs harvested from 129+/+ and Nlrp1b−/− mice
after treatment with 20 μg LT i.t. Lungs were harvested at the indicated times (A) – (H), at
48 h (I, L) or at 72 h in (J, K, M and N). Scale bars represent 250 μm for (A – H) and 10 μm
for (I – N). Original magnification was 2 x for (A – H) and 40x for (I – N).
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Figure 7. Lethal toxin-induced lung injury is dependent on caspase-1 but not IL-1β
(A–E) Casp-1+/+ (black) and Casp-1 −/− (shade) mice were treated with PBS as a vehicle or
20 μg LT i.t. BAL fluid was collected at 72 h after treatment. (A) The total number of
inflammatory cells collected in the BAL fluid. (B) Cell death in BAL fluid determined by
LDH activity in supernatants and expressed as the percentage of total cellular LDH activity.
(C) Vascular permeability evaluated as a concentration of albumin in the BAL fluid,
measured by colorimetric assay. KC (D) and CXCL15/lungkine (E) in the BAL fluid were
detected by ELISA. n = 2 mice per genotype for vehicle treatment and n = 10 mice per
genotype for LT treatment. (F, G) Il1β+/+ (black) and Il1β−/−(striped) mice were treated as
above. (F) The total number of inflammatory cells collected in BAL fluid. (G) The
percentage of weight lost 72 h after treatment. n= 2 per genotype for vehicle treatment and n
= 9 mice per genotype for LT treatment. * p < 0.05; ** p < 0.01; # p < 0.0001.
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Figure 8. Lethal toxin activates caspase-1 in the lung independently on P2X7 receptor
(A–B) 129+/+, Nlrp1b−/−, and Casp-1−/− mice were treated with 20 μg of LT by i.t. BAL
fluid was collected 2 h after treatment, and cells were stained with fluorescently labeled
caspase inhibitors and with 7-Amino-Actinomycin (7-AAD), n=4 per genotype. Cells were
analyzed on FACS and compared to untreated controls. (A) Data is expressed as the
difference in median fluorescent intensity (MFI) in the LT-treated mice and untreated mice.
(B) A representative overlay of the untreated (gray filled) and LT-treated (black line) cell
populations. (C–F) BALB/c or P2X7−/− mice were treated with 20 μg LT i.t. BAL fluid
was collected at 72 h after treatment. (C) The total number of inflammatory cells collected
in the BAL fluid. (D) Vascular permeability evaluated as a concentration of protein in the
BAL fluid, measured by BCA assay. (E) Cell death in BAL fluid determined by LDH
activity in supernatants. (F) KC in the BAL fluid was detected by ELISA, n=5 mice per
genotype. * p < 0.05; ** p < 0.01 ***p<0.001 compared to WT.
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